title: [A case of imatinib-resistant GIST treated by sunitinib].
abstract: We report a case of imatinib-resistant GIST, successfully treated by sunitinib. A 62-year-old man with high-grade fever and a huge abdominal tumor was diagnosed with malignant GIST and multiple liver metastases. We performed total gastrectomy combined with distal pancreatectomy, and splenectomy for palliation. Imatinib at a dose of 300mg/day was administered postoperatively, and the liver metastases was well controlled. After nine months, abdominal dissemination increased, and we raised the dose of imatinib to 400mg/day for the progressive state. Subsequently, we had to discontinue imatinib due to its adverse effects. Because the tumors progressed greatly while imatinib was discontinued, we changed to sunitinib. After wards, tumors reduced and his general condition improved remarkably. Although tumors progressed after five months, he was able to obtain good QOL during the administration of sunitinib. Sunitinib is useful for imatinib-resistant GIST, and may be a promising treatment even for patients with poor PS.
authors.affiliation: Dept. of Gastroenterological Surgery, National Kyushu Cancer Center.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Sakamoto
authors.forename: Hisafumi
authors.initials: H
authors.lastname: Akimoto
authors.forename: Miyako
authors.initials: M
authors.lastname: Kojo
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kawano
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Chinen
authors.forename: Kazutoyo
authors.initials: K
authors.lastname: Morita
authors.forename: Masahiko
authors.initials: M
authors.lastname: Sugiyama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Saeki
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Minami
authors.forename: Yuji
authors.initials: Y
authors.lastname: Soejima
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Sakaguchi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Toh
authors.forename: Takeshi
authors.initials: T
authors.lastname: Okamura
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use; D011788:Quality of Life; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D000077210:Sunitinib